Please login to the form below

Not currently logged in
Email:
Password:

Dr Michael Watson appointed as president of Valera

Former Sanofi Pasteur policy head joins Moderna Therapeutics firm

Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.

Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.

Stéphane Bancel, chief executive officer of Moderna, said: “We are thrilled to have Mike assume the helm of Valera, particularly at this critical inflection point for the company, as we continue to progress our clinical stage infectious disease pipeline.”

He joins the infectious diseases specialty firm from Sanofi Pasteur, where he most recently served as its global head of vaccination policy and advocacy and has also held the position of head of clinical and epidemiology in France.

Prior to this, Dr Watson has been head of research and development at Acambis and Aventis Pasteur MSD's medical director for the UK.

He is currently a member of the Board of Vaccines Europe and The Foundation for Innovative New Vaccines.

Dr Watson said: “The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting.

“Moderna's technology, coupled with its goal to deliver transformative medicines to millions of patients, makes this an extraordinary opportunity.

“I am eager and proud to join Valera and work with this outstanding team and Moderna's esteemed infectious disease-focused partners.”

13th April 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics